Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX ...
INDIANAPOLIS--(BUSINESS WIRE)--Today, Tangoe, a market leader in technology expense management and managed mobility services, announced the inaugural release of their 2021 Market Trends Report. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results